New Novus (300765): Short-term pressure on main business performance, continuous integration of innovative assets
New Novus (300765): Short-term performance is under pressure, research and development of new drugs continues to advance
New Novus (300765): From caffeine leader to CSPC Group's A-share innovative drug platform
Research Nuggets丨CITIC Construction Investment: New Novartis accelerates the layout of innovative pharmaceuticals, opens up room for future growth, and maintains a “buy” rating
New Novus (300765): Performance is in line with expectations, layout, innovative drugs open up room for future growth
Research Report Nuggets丨Huatai Securities: Maintaining New Novus's “Buy” Rating, Target Price 46.15 Yuan
New Novus (300765): Main business performance is steady, innovative assets are optimistic about continued integration
New Novus (300765): A share innovation platform for leading API transformation group
New Novi (300765) 2023 Third Quarter Report Review: API Business Remains Stable, Capital Increase Boulders Help Innovation
Novo (300765): Performance Meets Expectations, Capital Increase, Jushi Lays Out Innovative Drug Business
Novo Novi (300765): Short-term pressure on Q3 results increases innovative drug business opens up room for growth
Novi Novi (300765) Depth: Acarbose, the leader in the caffeine export market, and health products resonate
New Novi (300765): Proposed to increase capital in Jushi Biopharmaceutical Leader to increase innovative drug business
New Novo (300765): Caffeine price increases drive the company's impressive performance in 22 years
New Novo (300765): Higher caffeine prices bring impressive performance and are expected to achieve high growth throughout the year
New Novo (300765): Caffeine prices have entered a new steady state, and plans to buy Shiyao Shengxue to increase health
新诺威(300765)新股网下询价策略
New Novo (300765) IPO Quotation Report
New Norway (300765): report on the recommendation of offline purchase of new shares
No Data